Interpace Biosciences Inc
OTC:IDXG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Interpace Biosciences Inc
OTC:IDXG
|
US |
|
C
|
Come Sure Group (Holdings) Ltd
HKEX:794
|
HK |
Interpace Biosciences Inc
Interpace Biosciences, Inc. operates as a bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. The company is headquartered in Parsippany, New Jersey and currently employs 147 full-time employees. The Company’s clinical services provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer in personalized medicine for improved patient diagnosis and management. Through its pharma services, it develops, commercializes and provides molecular and biomarker-based tests and services. Its pharma services provide pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries and advance personalized medicine. The firm has five commercialized molecular diagnostic tests in the marketplace, which include PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR and RespriDx. Its pipeline product includes BarreGEN.
Interpace Biosciences, Inc. operates as a bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. The company is headquartered in Parsippany, New Jersey and currently employs 147 full-time employees. The Company’s clinical services provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer in personalized medicine for improved patient diagnosis and management. Through its pharma services, it develops, commercializes and provides molecular and biomarker-based tests and services. Its pharma services provide pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries and advance personalized medicine. The firm has five commercialized molecular diagnostic tests in the marketplace, which include PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR and RespriDx. Its pipeline product includes BarreGEN.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
